{
  "address1": "777 Old Saw Mill River Road",
  "city": "Tarrytown",
  "state": "NY",
  "zip": "10591-6707",
  "country": "United States",
  "phone": "914 847 7000",
  "website": "https://www.regeneron.com",
  "industry": "Biotechnology",
  "industryKey": "biotechnology",
  "industryDisp": "Biotechnology",
  "sector": "Healthcare",
  "sectorKey": "healthcare",
  "sectorDisp": "Healthcare",
  "longBusinessSummary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.",
  "fullTimeEmployees": 15182,
  "companyOfficers": [
    {
      "maxAge": 1,
      "name": "Dr. Leonard S. Schleifer M.D., Ph.D.",
      "age": 71,
      "title": "Co-Founder, President, CEO & Co-Chairman",
      "yearBorn": 1953,
      "fiscalYear": 2024,
      "totalPay": 6823034,
      "exercisedValue": 117275128,
      "unexercisedValue": 192379808
    },
    {
      "maxAge": 1,
      "name": "Dr. George D. Yancopoulos M.D., Ph.D.",
      "age": 64,
      "title": "Co-Founder, President, Chief Scientific Officer & Co-Chairman",
      "yearBorn": 1960,
      "fiscalYear": 2024,
      "totalPay": 6796783,
      "exercisedValue": 95717904,
      "unexercisedValue": 188321072
    },
    {
      "maxAge": 1,
      "name": "Mr. Christopher R. Fenimore CPA",
      "age": 53,
      "title": "Executive VP of Finance & CFO",
      "yearBorn": 1971,
      "fiscalYear": 2024,
      "totalPay": 1269250,
      "exercisedValue": 9054700,
      "unexercisedValue": 16618295
    },
    {
      "maxAge": 1,
      "name": "Dr. Andrew J. Murphy Ph.D.",
      "age": 66,
      "title": "Executive Vice President of Research",
      "yearBorn": 1958,
      "fiscalYear": 2024,
      "totalPay": 1613560,
      "exercisedValue": 26279800,
      "unexercisedValue": 56244512
    },
    {
      "maxAge": 1,
      "name": "Mr. Daniel P. Van Plew",
      "age": 51,
      "title": "Executive VP and GM of Industrial Operations & Product Supply",
      "yearBorn": 1973,
      "fiscalYear": 2024,
      "totalPay": 1905481,
      "exercisedValue": 20283170,
      "unexercisedValue": 9502018
    },
    {
      "maxAge": 1,
      "name": "Mr. Rajesh  Ahuja",
      "title": "Senior Vice President of Quality Assurance & Operations",
      "fiscalYear": 2024,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Bob  McCowan",
      "title": "Senior VP of IT & Chief Information Officer",
      "fiscalYear": 2024,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Ryan  Crowe",
      "title": "Senior Vice President of Investor Relations & Strategic Analysis",
      "fiscalYear": 2024,
      "exercisedValue": 0,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Mr. Joseph J. LaRosa J.D.",
      "age": 65,
      "title": "Executive VP, General Counsel & Secretary",
      "yearBorn": 1959,
      "fiscalYear": 2024,
      "totalPay": 1748110,
      "exercisedValue": 23227300,
      "unexercisedValue": 0
    },
    {
      "maxAge": 1,
      "name": "Ms. Melissa  Lozner",
      "title": "Senior VP & Chief Compliance Officer",
      "fiscalYear": 2024,
      "exercisedValue": 0,
      "unexercisedValue": 0
    }
  ],
  "auditRisk": 8,
  "boardRisk": 10,
  "compensationRisk": 9,
  "shareHolderRightsRisk": 10,
  "overallRisk": 10,
  "governanceEpochDate": 1756684800,
  "compensationAsOfEpochDate": 1735603200,
  "irWebsite": "http://newsroom.regeneron.com/",
  "executiveTeam": [],
  "maxAge": 86400,
  "priceHint": 2,
  "previousClose": 560.0,
  "open": 558.54,
  "dayLow": 558.54,
  "dayHigh": 573.69,
  "regularMarketPreviousClose": 560.0,
  "regularMarketOpen": 558.54,
  "regularMarketDayLow": 558.54,
  "regularMarketDayHigh": 573.69,
  "dividendRate": 3.52,
  "dividendYield": 0.63,
  "exDividendDate": 1755475200,
  "payoutRatio": 0.0444,
  "beta": 0.35,
  "trailingPE": 14.422922,
  "forwardPE": 12.637166,
  "volume": 930221,
  "regularMarketVolume": 930221,
  "averageVolume": 989582,
  "averageVolume10days": 926680,
  "averageDailyVolume10Day": 926680,
  "bid": 571.63,
  "ask": 573.82,
  "bidSize": 1,
  "askSize": 2,
  "marketCap": 60687097856,
  "fiftyTwoWeekLow": 476.49,
  "fiftyTwoWeekHigh": 1165.85,
  "priceToSalesTrailing12Months": 4.2694697,
  "fiftyDayAverage": 563.9462,
  "twoHundredDayAverage": 621.93134,
  "trailingAnnualDividendRate": 1.76,
  "trailingAnnualDividendYield": 0.0031428572,
  "currency": "USD",
  "tradeable": false,
  "enterpriseValue": 53300465664,
  "profitMargins": 0.31367,
  "floatShares": 97886130,
  "sharesOutstanding": 104170000,
  "sharesShort": 2827689,
  "sharesShortPriorMonth": 2291886,
  "sharesShortPreviousMonthDate": 1753920000,
  "dateShortInterest": 1756425600,
  "sharesPercentSharesOut": 0.026700001,
  "heldPercentInsiders": 0.01935,
  "heldPercentInstitutions": 0.90211,
  "shortRatio": 2.8,
  "shortPercentOfFloat": 0.028199999,
  "impliedSharesOutstanding": 105987000,
  "bookValue": 287.55,
  "priceToBook": 1.9912713,
  "lastFiscalYearEnd": 1735603200,
  "nextFiscalYearEnd": 1767139200,
  "mostRecentQuarter": 1751241600,
  "earningsQuarterlyGrowth": -0.028,
  "netIncomeToCommon": 4458599936,
  "trailingEps": 39.7,
  "forwardEps": 45.31,
  "enterpriseToRevenue": 3.75,
  "enterpriseToEbitda": 11.933,
  "52WeekChange": -0.5143442,
  "SandP52WeekChange": 0.16885936,
  "lastDividendValue": 0.88,
  "lastDividendDate": 1755475200,
  "quoteType": "EQUITY",
  "currentPrice": 572.59,
  "targetHighPrice": 890.0,
  "targetLowPrice": 543.0,
  "targetMeanPrice": 716.8729,
  "targetMedianPrice": 740.0,
  "recommendationMean": 1.76,
  "recommendationKey": "buy",
  "numberOfAnalystOpinions": 24,
  "totalCash": 7469599744,
  "totalCashPerShare": 72.04,
  "ebitda": 4466800128,
  "totalDebt": 2705100032,
  "quickRatio": 3.567,
  "currentRatio": 4.598,
  "totalRevenue": 14214200320,
  "debtToEquity": 9.035,
  "revenuePerShare": 133.029,
  "returnOnAssets": 0.06656,
  "returnOnEquity": 0.15336001,
  "grossProfits": 6730500096,
  "freeCashflow": 2850962432,
  "operatingCashflow": 4743499776,
  "earningsGrowth": 0.032,
  "revenueGrowth": 0.036,
  "grossMargins": 0.47351003,
  "ebitdaMargins": 0.31425,
  "operatingMargins": 0.29641,
  "financialCurrency": "USD",
  "symbol": "REGN",
  "language": "en-US",
  "region": "US",
  "typeDisp": "Equity",
  "quoteSourceName": "Nasdaq Real Time Price",
  "triggerable": true,
  "customPriceAlertConfidence": "HIGH",
  "shortName": "Regeneron Pharmaceuticals, Inc.",
  "longName": "Regeneron Pharmaceuticals, Inc.",
  "corporateActions": [],
  "postMarketTime": 1757967188,
  "regularMarketTime": 1757966400,
  "exchange": "NMS",
  "messageBoardId": "finmb_33715",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EDT",
  "gmtOffSetMilliseconds": -14400000,
  "market": "us_market",
  "esgPopulated": false,
  "marketState": "POST",
  "regularMarketDayRange": "558.54 - 573.69",
  "fullExchangeName": "NasdaqGS",
  "averageDailyVolume3Month": 989582,
  "fiftyTwoWeekLowChange": 96.10004,
  "fiftyTwoWeekLowChangePercent": 0.20168322,
  "fiftyTwoWeekRange": "476.49 - 1165.85",
  "fiftyTwoWeekHighChange": -593.25995,
  "fiftyTwoWeekHighChangePercent": -0.50886476,
  "fiftyTwoWeekChangePercent": -51.43442,
  "dividendDate": 1756857600,
  "regularMarketChangePercent": 2.248219,
  "regularMarketPrice": 572.59,
  "fiftyDayAverageChange": 8.643799,
  "fiftyDayAverageChangePercent": 0.015327346,
  "twoHundredDayAverageChange": -49.34131,
  "twoHundredDayAverageChangePercent": -0.07933562,
  "sourceInterval": 15,
  "exchangeDataDelayedBy": 0,
  "averageAnalystRating": "1.8 - Buy",
  "cryptoTradeable": false,
  "hasPrePostMarketData": true,
  "firstTradeDateMilliseconds": 670602600000,
  "postMarketChangePercent": -1.4128829,
  "postMarketPrice": 564.5,
  "postMarketChange": -8.090027,
  "regularMarketChange": 12.590027,
  "earningsTimestamp": 1754051400,
  "earningsTimestampStart": 1761827400,
  "earningsTimestampEnd": 1761827400,
  "earningsCallTimestampStart": 1754051400,
  "earningsCallTimestampEnd": 1754051400,
  "isEarningsDateEstimate": true,
  "epsTrailingTwelveMonths": 39.7,
  "epsForward": 45.31,
  "epsCurrentYear": 39.37253,
  "priceEpsCurrentYear": 14.54288,
  "displayName": "Regeneron Pharmaceuticals",
  "trailingPegRatio": 1.0771
}